Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Med30 CRISPR/Cas9 KO Plasmid (h): sc-406399
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Med30 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Med30 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Med30 Antibody (C-6): sc-393289
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Med30 CRISPR/Cas9 KO Plasmid (h) | sc-406399 | 20 µg | $397.00 |
Overview
MED30 encodes a core subunit of the Mediator complex that couples sequence-specific transcription factors to RNA polymerase II, enabling regulated transcription initiation and promoter-dependent gene expression. Med30 contributes to Mediator structural integrity and supports coordinated transcriptional programs that govern cell-cycle progression, differentiation, and stress-responsive signaling. Because Mediator integrates multiple signaling inputs, perturbation of MED30 can alter transcriptional networks implicated in proliferative control and cellular homeostasis. Dysregulated Mediator function is frequently associated with disease-relevant gene expression states, making MED30 a useful node for studying transcriptional circuitry in human cells.
Med30 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MED30 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MED30 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MED30 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Med30 protein expression.
This CRISPR knockout system enables efficient generation of MED30-deficient cell models for investigation of Med30 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MED30 exon(s) critical for Med30 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MED30 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Med30 CRISPR/Cas9 KO Plasmid (h) and Med30 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MED30 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Med30 HDR Plasmid (h) and Med30 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MED30 homology arms to support homology-directed repair at defined MED30 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.